Journal of Fertility Biomarkers publishes rigorous fertility biomarker research that advances diagnosis, treatment, and reproductive outcomes.

Follow these guidelines to ensure a smooth editorial review and production process.

• Use clear, concise language and define all abbreviations
• Include structured abstracts with objectives, methods, results, and conclusions
• Provide keywords that reflect fertility biomarker types and methods
• Ensure references are complete and include DOIs where available

• STROBE for observational studies
• CONSORT for randomized trials
• PRISMA for systematic reviews
• CARE for case reports
• TREND for non randomized evaluations

• Include ethics approvals and informed consent statements
• Provide data availability statements and repository links
• Describe diagnostic criteria and outcome definitions
• Document patient privacy safeguards and deidentification

• Specify assay platform, calibration, and QC thresholds
• Report sample timing relative to cycle or treatment
• Provide reference ranges and units for biomarker values
• Describe specimen handling and storage conditions
• Report clinical outcome definitions linked to biomarker analysis
• Include sensitivity analyses for key biomarkers

• Title page with author affiliations and corresponding author details
• Abstract and keywords
• Introduction describing clinical context and research gap
• Methods including assay validation and treatment protocols
• Results with tables, figures, and statistical analysis
• Discussion highlighting implications for clinical care

Provide high resolution figures and editable tables. Ensure all units and abbreviations are defined. Figures should be cited in order and include descriptive captions.

• Cover letter explaining novelty and clinical relevance
• Conflict of interest and funding disclosures
• Ethics approvals and consent documentation
• Data availability statement
• Figure and table files uploaded
• Define the primary biomarker category (hormonal, imaging, genomic, proteomic, or metabolomic).
• Report assay platform, manufacturer, and kit lot numbers where applicable.
• Provide sample collection timing relative to cycle day or stimulation phase.
• Describe specimen type and handling conditions (serum, plasma, follicular fluid, semen).
• Include storage temperature, freeze thaw cycles, and transport timelines.
• Provide calibration procedures and quality control ranges.
• Report intra assay and inter assay variability.
• Specify detection limits and linearity ranges for biomarker assays.
• Use standardized units and reference ranges for all biomarkers.
• Define cohort inclusion and exclusion criteria in detail.
• Report infertility diagnosis categories (PCOS, endometriosis, male factor, unexplained).
• Describe ovarian reserve markers measured (AMH, FSH, AFC).
• Provide ultrasound methodology and counting criteria for AFC.
• Report hormonal assay timing (follicular, luteal, trigger day).
• Describe stimulation protocol details and medications.
• Provide number of oocytes retrieved and maturity rates.
• Report fertilization method (IVF or ICSI).
• Provide embryo grading criteria and day of assessment.
• Include morphokinetic parameters if time lapse imaging is used.
• Report PGT methods and indications when relevant.
• Describe endometrial assessment method and timing.
• Define implantation, clinical pregnancy, and live birth outcomes.
• Report miscarriage and obstetric outcome definitions.
• Include male factor biomarker measures (DNA fragmentation, ROS, motility).
• Provide semen analysis standards and WHO reference criteria.
• Report abstinence period for semen samples.
• Describe laboratory equipment and imaging settings.
• Provide statistical power and sample size justification.
• Adjust for confounders such as age, BMI, and smoking.
• Report handling of repeated cycles per patient.
• Describe blinding and randomization when applicable.
• Provide missing data handling and sensitivity analyses.
• Include external validation or replication cohorts.
• Provide model performance metrics for predictive tools.
• Report calibration and discrimination metrics for models.
• Describe feature selection and preprocessing steps for omics data.
• Provide batch effect correction methods for omics datasets.
• State ethics approvals and consent procedures.
• Provide data availability statements and repository links.
• Describe clinical decision thresholds for biomarker adoption.
• Report cost or resource implications when relevant.
• Include patient reported outcomes when collected.
• Describe geographic and demographic diversity of the cohort.
• Report laboratory accreditation status when applicable.
• Provide assay cross reactivity information.
• Describe quality assurance procedures in the lab.
• Report time from sample collection to analysis.
• Include details on environmental or lifestyle covariates.
• Describe ovarian stimulation response metrics.
• Report luteal phase support regimens when applicable.
• Include details on cryopreservation methods.
• Report embryo transfer protocols (fresh vs frozen).
• Provide endometrial thickness measurement technique.
• Describe imaging interpretation criteria for biomarkers.
• Report follow up duration for outcomes.
• Include limitations regarding generalizability.
• Provide clinical utility statements for biomarker adoption.
• Report multi omics integration methods when used.
• Document data governance for genetic results.
• Provide reproducibility materials or code access details.
• Provide a structured abstract with clear objectives, methods, results, and conclusions.
• Use consistent fertility biomarker terminology and define abbreviations at first use.
• Include a data availability statement with repository links or accession numbers.
• Report statistical tests, effect sizes, and confidence intervals where applicable.
• Describe patient cohorts, inclusion criteria, and infertility diagnosis categories.
• Provide detailed treatment protocols and cycle monitoring methods.
• Report imaging modalities, timing, and diagnostic thresholds.
• Include clear figure legends and indicate sample sizes and data sources.
• Confirm references include DOIs where available and match in text citations.
• Disclose funding sources, grant numbers, and potential conflicts of interest.
• Report ethics approvals, informed consent, and privacy safeguards.
• Clarify guidelines referenced and any deviations.
• Include a brief limitations statement that addresses generalizability.
• Provide repository links for code, models, or analysis scripts when shared.
• State whether preprints exist and disclose prior dissemination.
• Describe how raw data and code can be accessed, including access controls.
• Report quality control for lab assays or imaging review.
• Include details on adverse event monitoring for treatments.
• Provide response criteria used for clinical outcomes.
• Clarify primary and secondary endpoint definitions and timing.
• Report trial registration identifiers when applicable.
• Define units for all measurements and ensure consistent reporting.
• Include details on imaging protocols and reporting standards.
• Report assay adequacy rates and handling of out of range values.
• Clarify definitions for biochemical and clinical outcomes.
• Provide criteria used for treatment selection decisions.
• Include details on embryo grading and endometrial assessment reporting.
• Report protocol deviations and their impact on outcomes.
• Describe adjustments for competing risks in survival analyses.
• Provide subgroup analyses by diagnosis or treatment pathway when applicable.
• Report complication grading scales used.
• Include imaging response criteria for relevant outcomes.
• Describe follow up frequency and lost to follow up handling.
• Provide clear definitions for treatment response categories.
• Describe assay validation and calibration methods in detail.
• Report sample handling and storage protocols when relevant.
• Include details on embryo transfer timing and luteal support.
• Clarify definitions for biochemical response and clinical pregnancy.
• Provide protocols for follow up imaging and laboratory monitoring.
• Report criteria for selecting treatment pathways.
• Describe handling of hormone suppression or stimulation strategies.
• Include details on management of incidental findings.

JFB is committed to rigorous, transparent publishing in fertility biomarker research and reproductive medicine. We emphasize reproducible laboratory methods, clear reporting of diagnostic criteria, and ethical compliance across all article types.

The editorial office supports authors, editors, and reviewers with clear guidance and responsive communication. For questions about scope or workflow, contact [email protected].

We encourage continuous improvement in reporting practices and share updates that help the community maintain high standards in biomarker validation, reproductive outcomes, and translational fertility science.